Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

IDERHA Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance

Coordinator
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV, Germany
Runs
1 April 2023 to 31 March 2028
Status
Running
EU funding
€23.0m
Total cost
€36.2m
Partners
39 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101112135

What the project is doing

In the project's own words, from its summary on CORDIS.

IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced regulatory and HTA decision-making recommendations for integrated health research, with the aim to improve care and better meet the needs of patients and health care professionals. The IDERHA open platform for multi-modal health data will enhance innovation in EU health care systems and is directly scalable by means of connecting additional systems, data sources and additional services and tools.

It will extend and elaborate standards in semantic interpretation, data quality, ethics and transferability to ensure the harmonisation of heterogeneous data sources and wider health data reuse. Use cases positioned along the lung cancer patient pathway will be implemented using retrospective data and in a remote patient care context. These practical implementations will demonstrate the added value of multi-modal data aggregation and analysis with impacts expected on public health, patient burden, health outcomes and cost.

We will perform AI/ML based lung-cancer risk profiling using patient`s EHRs, and improved CT image- based AI/ML to provide risk prediction of potential lung cancer patients, and explore the possibilility of personal prognosis of disease progression. Using patient monitoring and engagement, including digital biomarker, PROMs, and connected devices, the IDERHA platform will enable remote patient monitoring, and provide data for joint patient-health professional decision making.

Along with health care stakeholders, IDERHA will develop consensus policy recommendations for appropriate data sharing to enable multi-stakeholder research. Informed by Patient Advisory Groups, we will address critical obstacles and issues to heterogeneous health data primary and secondary use. Regulatory and HTA agencies will be engaged to create criteria for assessing the acceptability of heterogeneous health research results in regulatory and HTA decision-making.

Topics

Who is involved

OrganisationCityCountryRole
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyCoordinator
Fachhochschule Technikum WienWienAustriaParticipant
Ludwig Boltzmann Gesellschaft Osterreichische Vereinigung Zur Forderung Der Wissenschaftlichen ForschungWienAustriaParticipant
Medizinische Universitaet WienWienAustriaParticipant
European Cancer Patient CoalitionBruxelles / BrusselBelgiumParticipant
Fortrea BelgiumBruxelles / BrusselBelgiumParticipant
Forum Des Patients EuropeensBruxelles / BrusselBelgiumParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Johnson & Johnson Medical NVMachelenBelgiumParticipant
Q1.6 BVAntwerpenBelgiumParticipant
The European Institute for Innovation Through Health DataGentbruggeBelgiumParticipant
European Respiratory SocietyLausanneSwitzerlandAssociatedpartner
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Hygiaso AGBaselSwitzerlandAssociatedpartner
Lung Cancer Europe LuceBernSwitzerlandAssociatedpartner
Takeda Pharmaceuticals International AGGlattparkSwitzerlandParticipant
Asklepios Kliniken Hamburg GmbHHamburgGermanyParticipant
Janssen-Cilag GmbHNeussGermanyThird party
Johnson & Johnson Medical GmbHNorderstedtGermanyParticipant
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyParticipant
Msb Medical School Berlin GmbHBerlinGermanyParticipant
LaegemiddelstyrelsenKobenhavn SDenmarkParticipant
Region MidtjyllandViborgDenmarkParticipant
Fundacion Para La Gestion De La Investigacion En Salud De SevillaSevillaSpainThird party
Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad ValencianaValenciaSpainParticipant
Servicio Andaluz De SaludSevillaSpainParticipant
Servizo Galego De SaudeSantiago De CompostelaSpainParticipant
Teknologian Tutkimuskeskus VTT OyEspooFinlandParticipant
Sanofi-Aventis Recherche & DeveloppementGentillyFranceParticipant
Information Technology for Translational Medicine (ittm) SAEsch-UelzechtLuxembourgParticipant
Universite Du LuxembourgEsch-Sur-AlzetteLuxembourgParticipant
Janssen Vaccines & Prevention BVLeidenNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsParticipant
Philips Medical Systems Nederland BVBestNetherlandsParticipant
Stichting LygatureUtrechtNetherlandsParticipant
Janssen Cilag LimitedHigh WycombeUnited KingdomThird party
Labcorp Early Development Laboratories LimitedHarrogateUnited KingdomParticipant
National Institute for Health and Care ExcellenceManchesterUnited KingdomAssociatedpartner
Medical Device Business Services IncWarsawUnited StatesThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI